International Securities Identification Number

Mintos launches high-yield Fractional Bonds for retail investors

Retrieved on: 
Mardi, octobre 17, 2023

Historically bonds, and especially high-yield bonds, have predominantly been within reach of institutional investors or individuals wielding substantial capital, making them notably less accessible to retail investors.

Key Points: 
  • Historically bonds, and especially high-yield bonds, have predominantly been within reach of institutional investors or individuals wielding substantial capital, making them notably less accessible to retail investors.
  • Initially, Mintos will offer investments in high-yield corporate bonds issued by the lending companies present on the Mintos platform.
  • To access high-yield bonds on Mintos, investors invest in Fractional Bonds, asset-backed securities issued by Mintos special purpose entity that fully reflect the economic gains and capital repayments tied to specific underlying bonds.
  • For more information about Mintos and the Fractional Bonds, please visit Mintos bonds .

Mintos launches high-yield Fractional Bonds for retail investors

Retrieved on: 
Mardi, octobre 17, 2023

Historically bonds, and especially high-yield bonds, have predominantly been within reach of institutional investors or individuals wielding substantial capital, making them notably less accessible to retail investors.

Key Points: 
  • Historically bonds, and especially high-yield bonds, have predominantly been within reach of institutional investors or individuals wielding substantial capital, making them notably less accessible to retail investors.
  • Initially, Mintos will offer investments in high-yield corporate bonds issued by the lending companies present on the Mintos platform.
  • To access high-yield bonds on Mintos, investors invest in Fractional Bonds, asset-backed securities issued by Mintos special purpose entity that fully reflect the economic gains and capital repayments tied to specific underlying bonds.
  • For more information about Mintos and the Fractional Bonds, please visit Mintos bonds .

EQS-News: SCHOTT Pharma IPO: Final offer price set at EUR 27.00 per share

Retrieved on: 
Mercredi, septembre 27, 2023

Free float expected to amount up to 23% of outstanding share capital, assuming full exercise of the Greenshoe option

Key Points: 
  • Free float expected to amount up to 23% of outstanding share capital, assuming full exercise of the Greenshoe option
    First day of trading on the Frankfurt Stock Exchange scheduled for September 28, 2023
    The final offer price for the initial public offering (IPO) of SCHOTT Pharma AG & Co. KGaA (“SCHOTT Pharma” or “Company”) was set at EUR 27.00 per share today.
  • This corresponds to a placement volume of EUR 935 million and an expected free float of up to 23% assuming a full exercise of the Greenshoe option.
  • After the IPO, SCHOTT Glaswerke Beteiligungs- und Export GmbH (a wholly-owned subsidiary of SCHOTT AG – “Selling Shareholder”) will retain a stake of at least 77% of SCHOTT Pharma’s share capital as a long-term committed shareholder.
  • “With its compelling business model and attractive financial profile, SCHOTT Pharma has attracted a global investor base.

MariaDB Rule 2.12 Announcement

Retrieved on: 
Mardi, septembre 26, 2023

MariaDB plc (NYSE: MRDB) (the “Company”), in accordance with Rule 2.12 of the Irish Takeover Rules, confirms that as of September 22, 2023 its issued ordinary share capital was comprised of 67,713,368 ordinary shares, nominal value $0.01 per share (the "Ordinary Shares").

Key Points: 
  • MariaDB plc (NYSE: MRDB) (the “Company”), in accordance with Rule 2.12 of the Irish Takeover Rules, confirms that as of September 22, 2023 its issued ordinary share capital was comprised of 67,713,368 ordinary shares, nominal value $0.01 per share (the "Ordinary Shares").
  • The Ordinary Shares are admitted to trading on the New York Stock Exchange under the ticker symbol MRDB.
  • The Company confirms that as of September 22, 2023, there were outstanding warrants to subscribe for an aggregate of 16,351,314 Ordinary Shares.
  • The Company has 25,000 Deferred Ordinary Shares which are held as treasury shares.

Horizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement

Retrieved on: 
Mercredi, septembre 6, 2023

In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on September 5, 2023, Horizon’s issued ordinary share capital is comprised of 229,214,753 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each.

Key Points: 
  • In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on September 5, 2023, Horizon’s issued ordinary share capital is comprised of 229,214,753 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each.
  • The Company has 384,366 Ordinary Shares which are held as treasury shares.
  • The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol “HZNP”.
  • The International Securities Identification Number for these securities is IE00BQPVQZ61.

iCoreConnect Announces Clarification Regarding Trading of Common Stock, Warrants and Preferred Stock

Retrieved on: 
Lundi, août 28, 2023

FGMC common stock that was not redeemed in connection with the business combination was exchanged for preferred stock of the combined company that will trade on the OTC market.

Key Points: 
  • FGMC common stock that was not redeemed in connection with the business combination was exchanged for preferred stock of the combined company that will trade on the OTC market.
  • The initial conversion price from common stock to preferred stock was at a conversion price of $10.00 per share.
  • FGMC warrants have been converted into warrants for preferred stock of the combined company that will trade on the OTC market.
  • Common stock, warrants and preferred stock of the combined company will each begin trading under a new CUSIP and ISIN (International Securities Identification Number) on August 28, 2023.

Horizon Therapeutics plc - Rule 2.12 Announcement

Retrieved on: 
Mercredi, août 9, 2023

In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on June 30, 2023, Horizon’s issued ordinary share capital is comprised of 228,939,027 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each.

Key Points: 
  • In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on June 30, 2023, Horizon’s issued ordinary share capital is comprised of 228,939,027 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each.
  • The Company has 384,366 Ordinary Shares which are held as treasury shares.
  • The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol “HZNP”.
  • The International Securities Identification Number for these securities is IE00BQPVQZ61.

EQS-News: Final offer price for shares in thyssenkrupp nucera set at EUR 20.00 per share

Retrieved on: 
Mercredi, juillet 5, 2023

In total, 30,262,250 shares (including over-allotments)  are being placed with investors thereof 26,315,000 new shares, corresponding to an IPO size of approximately EUR 605 million.

Key Points: 
  • In total, 30,262,250 shares (including over-allotments)  are being placed with investors thereof 26,315,000 new shares, corresponding to an IPO size of approximately EUR 605 million.
  • The final offer price implies a market capitalization of thyssenkrupp nucera of EUR 2.53 billion.
  • Werner Ponikwar, CEO of thyssenkrupp nucera said: “We are proud that in terms of placement volume thyssenkrupp nucera is the largest global hydrogen IPO of all times.
  • I would like to thank our dedicated colleagues worldwide.”
    Arno Pfannschmidt, CFO of thyssenkrupp nucera said: “The IPO in the current market environment proves thyssenkrupp nucera right.

Santhera Publishes Timeline of the Reverse Share Split

Retrieved on: 
Jeudi, juin 29, 2023

53 LR

Key Points: 
  • 53 LR
    Pratteln, Switzerland, June 29, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the timeline of the reverse share split in the ratio 10:1 which was approved by shareholders at the Annual General Meeting held on June 27, 2023, with a large majority.
  • This is the case if shareholders hold a number of Santhera shares that is not divisible by 10 as of June 30, 2023.
  • Remaining shareholdings between 1 and 9 are rounded down and affected shareholders will receive a cash compensation (in CHF) for their fractions corresponding to a three-day volume-weighted average price (VWAP) of the Santhera share on the SIX Swiss Exchange prior to the ex-date of the reverse share split.
  • The new shares issued following the reverse stock split will have a new International Securities Identification Number (ISIN) while the existing shares held prior to the reverse stock split will be canceled.

Horizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement

Retrieved on: 
Mardi, juin 13, 2023

In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on June 9, 2023, Horizon’s issued ordinary share capital is comprised of 228,928,661 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each.

Key Points: 
  • In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on June 9, 2023, Horizon’s issued ordinary share capital is comprised of 228,928,661 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each.
  • The Company has 384,366 Ordinary Shares which are held as treasury shares.
  • The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol “HZNP”.
  • The International Securities Identification Number for these securities is IE00BQPVQZ61.